Table 1.
Baseline characteristics of 39 patients with high-risk non-Hodgkin’s lymphoma
| Characteristic | R-CHOP [cases (%)] | CHOP [cases (%)] | P value |
|---|---|---|---|
| Total | 14 | 25 | |
| Sex | 0.673 | ||
| Male | 8 (57.1) | 16 (64.0) | |
| Female | 6 (42.9) | 9 (36.0) | |
| Tumor origin | <0.001 | ||
| B-cell | 14 (100.0) | 8 (32.0) | |
| T-cell | 0 | 15 (60.0) | |
| NA | 0 | 2 (8.0) | |
| Ann arbor stage | 0.119 | ||
| I/II | 1 (7.1) | 8 (32.0) | |
| III/IV | 13 (92.9) | 17 (68.0) | |
| ECOG score | 0.289 | ||
| <2 | 13 (92.9) | 23 (92.0) | |
| ≥2 | 1 (7.1) | 2 (8.0) | |
| LDH level (IU/L) | 0.328 | ||
| >225 | 9 (64.3) | 12 (48.0) | |
| ≤225 | 5 (35.7) | 13 (52.0) | |
| B symptoms | 0.089 | ||
| No | 5 (35.7) | 16 (64.0) | |
| Yes | 9 (64.3) | 9 (36.0) | |
| Bulky disease | 0.431 | ||
| No | 6 (42.9) | 14 (56.0) | |
| Yes | 8 (57.1) | 11 (44.0) | |
| Extranodal invasion | 0.652 | ||
| No | 3 (21.4) | 7 (28.0) | |
| Yes | 11 (78.6) | 18 (72.0) | |
| aaIPI | 0.096 | ||
| 0–1 | 4 (28.6) | 15 (60.0) | |
| 2–3 | 10 (71.4) | 10 (20.0) | |
| Disease status before mobilization | 0.201 | ||
| CR | 8 (57.1) | 9 (36.0) | |
| PR | 6 (42.9) | 16 (64.0) | |
| Previous radiation therapy | 0 | 2 (8.0) | 0.528 |
R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimen; CHOP, CHOP or CHOP-like regimen without rituximab; ECOG Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; aaIPI age-adjusted International Prognostic Index; CR complete response; PR partial response; NA not available